Newport Coast, CA, United States of America

Ken Chow

USPTO Granted Patents = 124 

 

 

Average Co-Inventor Count = 4.8

ph-index = 10

Forward Citations = 503(Granted Patents)


Inventors with similar research interests:


Location History:

  • Irvine, CA (US) (1994 - 1996)
  • Newport Castle, CA (US) (2013)
  • Newport Coast, CA (US) (2001 - 2017)

Company Filing History:


Years Active: 1994-2017

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Alpha Adrenergic Receptor Modulators
Sphingosine-1-Phosphate Receptor Modulators
Oxadiazole Derivatives
Azetidine Derivatives
Pyrazole Derivatives
Therapeutic Compounds
Selective Adrenergic Agents
Bicyclic Compounds
Ester Pro-Drugs
Indole Modulators
Phenoxy Derivatives
Alkyne And Alkene Derivatives
124 patents (USPTO):Explore Patents

Title: Ken Chow: Pioneering Innovations in Treating α-Adrenergic Mediated Conditions

Introduction:

Ken Chow, a resident of Newport Coast, CA, is a prolific inventor and pioneer in the field of pharmaceutical compositions for the treatment of α-adrenergic mediated conditions. With an impressive portfolio of 124 patents, Chow has made significant contributions to the advancement of medical science and the alleviation of various types of pain.

Latest Patents:

Chow's most recent patents focus on methods of treating α-adrenergic mediated conditions through the administration of pharmaceutical compositions containing α-adrenergic modulators. These compounds have shown efficacy in treating a range of conditions, including pain, both acute and chronic, as well as neuropathic pain. These breakthroughs in treatment offer hope to patients suffering from diverse ailments.

Career Highlights:

Ken Chow's accomplishments extend beyond his groundbreaking patents. He has been associated with esteemed companies such as Allergan, Inc. and Allergan Sales, Inc. (commonly known as Allergan) throughout his career. While the presentation of Allergan's name may seem different, it is an abbreviation for International Business Machines Corporation, a significant player in the pharmaceutical industry.

Collaborations:

Collaboration has been a cornerstone of Chow's success, and he has worked alongside experts in the field, including Michael E. Garst and Todd M. Heidelbaugh. Such fruitful collaborations have fostered an environment of innovation, leading to the development of novel treatment strategies and formulations.

Conclusion:

With a remarkable record of 124 patents and a career marked by notable collaborations, Ken Chow has established himself as a leading figure in the field of pharmaceutical compositions for treating α-adrenergic mediated conditions. His contributions, particularly in the realm of alleviating diverse forms of pain, offer hope for enhanced quality of life for countless individuals. Chow's dedication to advancing medical science and improving patient outcomes continues to shape the landscape of innovative healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…